fig4

Profiling the gut and oral microbiota of hormone receptor-positive, HER2-negative metastatic breast cancer patients receiving pembrolizumab and eribulin

Figure 4. LEfSe analysis of the salivary microbiota data showed five genera associated with no-CB and one for CB (A). B. fragilis in the gut is associated with CB. LEfSe analysis (B) showed that B. fragilis is associated with CB. Box plots (C) further showed that patients with CB consistently had a greater relative abundance of B. fragilis than no-CB. This observation was most significant at EoT [Mann Whitney U: P = 0.009, U = 0, median (yes, no) = 1.95, 0.38, range (0.00-11.73)]. LEfSe: Linear discriminant analysis effect size; CB: clinical benefit.

Microbiome Research Reports
ISSN 2771-5965 (Online)

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/